International Stem Cell Corp. (OTCMKTS:ISCO) Short Interest Down 47.1% in February

International Stem Cell Corp. (OTCMKTS:ISCO) saw a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 5,059 shares, a decline of 47.1% from the February 12th total of 9,559 shares. Based on an average daily volume of 2,928 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.4% of the shares of the company are short sold. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 2,928 shares, the days-to-cover ratio is presently 1.7 days.

International Stem Cell Price Performance

OTCMKTS ISCO remained flat at $0.17 during trading hours on Thursday. The company’s stock had a trading volume of 1 shares, compared to its average volume of 3,955. The company’s 50 day moving average is $0.15 and its 200 day moving average is $0.14. International Stem Cell has a fifty-two week low of $0.09 and a fifty-two week high of $0.27. The company has a market capitalization of $1.34 million, a price-to-earnings ratio of -8.35 and a beta of 0.13.

About International Stem Cell

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.